4th Annual West Cancer Center Oncology Conference - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

4th Annual West Cancer Center Oncology Conference

WEST Oncology Conference – at Graceland®

Not a member of My prIME? Join now for instant access.

An update on practice-changing data on women’s cancers, genitourinary malignancies, hematologic malignancies, emerging issues in oncology, surgical oncology coordination, lung cancer, and a case-based discussion of the WCC molecular tumor board.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Nov 13, 2018

Expiration Date

Nov 13, 2019

Women's Cancer

Immunotherapy in gynecologic malignancies? Are we there yet?

Featured Expert: Rebecca Arend, MD

HER2-positive breast cancer: Beyond the plateau

Featured Expert: Sunil Verma, MD, MSEd, FRCPC

CDK 4/6 inhibitors: How to choose and where do we go from here?

Featured Expert: Angela DeMichele, MD, MSCE

Genitourinary Malignancies

Immunotherapy and targeted therapy for advanced kidney cancer: Are combinations ready for primetime?

Featured Expert: W. Kimryn Rathmell, MD, PhD

Immunotherapy and targeted therapy for advanced bladder cancer

Featured Expert: Derek Raghavan MD, PhD, FACP, FRACP, FASCO, FAAAS

The evolving role of germline mutation testing in GU cancers: Who, when, and how to test

Featured Expert: Brian Shuch, MD

Keynote

Clifton G. Hollis Memorial Lecture
A case of me: Clinical cancer sequencing – The future of precision medicine

Featured Expert: Lukas D. Wartman, MD

Hematologic Malignancies

Chimeric antigen receptor (CAR) and adoptive cell transfer: Review of the data and a roadmap to implementation in a community setting

Featured Expert: Frederick Locke, MD

AML in the Elderly

Featured Expert: John S. Welch, MD, PhD

DLBCL: Double-hit, triple-hit, and how to manage them

Featured Expert: Amanda Cashen, MD

Multiple myeloma: Updates on new and novel strategies

Featured Expert: Shaji Kumar, MD

Emerging Issues in Oncology

Geriatric oncology: The key is geriatric assessment

Featured Expert: Hyman B. Muss, MD

Palliative care: How to make the best of the worst

Featured Expert: Eric Roeland, MD

Emerging molecular biomarkers for IO: Looking beyond PD-1/PD-L1

Featured Expert: Melissa Johnson, MD

Surgical Oncology Coordination

Intrahepatic cholangiocarcinoma: Surgical and nonsurgical liver-directed therapy

Featured Expert: Paxton V. Dickson, MD, FACS

Extrahepatic bile duct cancers: Addressing the challenges of diagnosis, surgical therapy, and palliation

Featured Expert: Mark J. Truty, MD, MSc, FACS

Perspective on systemic therapies and molecular profiling for biliary tract cancers

Featured Expert: Milind Javle, MD

Resectable pancreatic cancer: What is the appropriate sequencing of therapy?

Featured Expert: Syed A. Ahmad, MD, FACS

Lung Cancer

Further updates on molecularly driven treatment of lung cancer

Featured Expert: Daniel B. Costa, MD, PhD, MMSc

This educational activity is specifically designed to meet the needs of practicing medical oncologists, hematologists, surgeons, radiation oncologists, pathologists, nurses, and other healthcare professionals involved in the treatment of cancer.

After successful completion of this educational activity, participants should be able to:

Physicians

  • Evaluate recent clinical data on the novel targeted and immunologic approaches for breast and ovarian cancers
  • Incorporate new diagnostic strategies and immunotherapy and targeted therapies into the treatment algorithms for genitourinary malignancies, including kidney, bladder, and prostate cancers
  • Discuss new and emerging treatment options for hematologic malignancies
  • Evaluate the role of surgery, radiation therapy, and systemic therapies for the treatment of pancreatic and bile duct cancers
  • Formulate strategies to integrate new and emerging targeted strategies and immunotherapy into standard treatment for lung cancer

Nurses

  • Identify the role of nurses in managing the practical challenges in providing optimal supportive care for cancer, including palliative care, pain management, and immune-related adverse event management

This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; Celgene Corporation; Clovis Oncology; and Novartis Oncology.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is jointly provided by The Annenberg Center for Health Sciences at Eisenhower, West Cancer Center and prIME Oncology in collaboration with Postgraduate Institute of Medicine.

Disclosure Information

Disclosure of Relevant Financial Relationships

Annenberg Center for Health Sciences at Eisenhower and prIME Oncology assess relevant financial relationships with their instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by Annenberg Center for Health Sciences at Eisenhower and prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. Annenberg Center for Health Sciences at Eisenhower and prIME Oncology are committed to providing their learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Ahmad has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Arend has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Cashen has disclosed membership on an advisory committee or review panel from Astellas and Verastem. She also disclosed speaking and teaching for Celgene and Seattle Genetics. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Chandler has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Costa has disclosed that he has received consulting fees from AstraZeneca, Pfizer, and Takeda. He also disclosed independent contracting for Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr DeMichele has disclosed as an independent contractor for Calithera, Genentech, Novartis, and Pfizer. She also disclosed speaking and teaching for Pfizer and Asian Clinical Oncology Society. Her spouse disclosed participation on a data safety monitory board for Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Dickson has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Pamela Dotson has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr ElNaggar has disclosed that he has received consulting fees from AstraZeneca, Clovis Oncology, and TESARO. He also disclosed speaking and teaching for AstraZeneca. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Fenton has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Fleming has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Natasha Goins has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Heather Greene has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Grothey has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hayes has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Javle has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Johnson has disclosed institutional research funds (no personal funds) to her institution for AbbVie; Adaptimmune; Amgen; Apexigen; Array BioPharma; AstraZeneca; BeiGene; BerGenBio; Birdie; Boehringer Ingelheim; Checkpoint Therapeutics; Corvus; Cytomx; Daiichi Sankyo; Dynavax; EMD Serono; G1 Therapeutics; Genentech/Roche; Genmab; Genocea; Gritstone; Hengrui Therapeutics, INC; Incyte; Janssen; Lilly; LOXO; Lycera; Merck; Mirati Therapeutics; Neovia; Novartis; Pfizer; Regeneron; Sanofi; Stemcentrix; Syndax; and Tarveda. She also disclosed that she received consulting fees for her institution from AstraZeneca, Boehringer Ingelheim, Calithera, Celgene, Genentech/Roche, LOXO, Merck, Mirati, and Sanofi. She disclosed that her spouse has received fees as a contract lobbyist from Astellas and Otsuka Pharmaceuticals. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Khaled has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Robert Koch has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kumar has disclosed that he has received consulting fees from AbbVie, Amgen, Celgene, Kite Pharma, Merck, Oncopeptides, Reddy’s Lab, and Takeda. He also disclosed independent contracting for AbbVie; Amgen; Bristol-Myers Squibb; Celgene; Kite Pharma; Medimmune; Merck and Co, Inc.; Roche; and Takeda. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Locke has disclosed that he has received consulting fees from Cellular Biomedicine Group Inc. He also disclosed membership on advisory committees or review panels for Kite Pharma and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Martin has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Muss has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Raghavan has disclosed receipt of a grant for lung cancer screening from the Bristol-Myers Squibb Foundation. He also disclosed unpaid membership on the Caris Life Sciences Medical Advisory Board.  He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Rathmell has disclosed that she has no relevant financial relationships to report. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Roeland has disclosed that he has received consulting fees from the Heron Advisory Board.  He also disclosed ownership interest in AIM Oncology. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Schwartzberg has disclosed that he has received consulting fees from Helsinn and Spectrum Pharmaceuticals. He also disclosed membership on advisory committees or review panels for Genomic Health, Myriad, and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Shibata has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Shuch has disclosed that he has received consulting fees from Peloton Therapeutics and Pfizer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Somer has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Truty has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vaena has disclosed that he has received consulting fees from AstraZeneca, Bristol-Myers Squibb, and Genomic Health. He disclosed as an independent contractor for Aeglea, AstraZeneca, Bioclin, Bristol-Myers Squibb, Calithera, Compugen, Merck, Nektar, Novartis, Peloton, TG Therapeutics, and Tizona. He also disclosed travel expenses received from Caris Life Sciences. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ari VanderWalde has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Noam VanderWalde has disclosed that he has no relevant financial relationships to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Verma has disclosed membership on advisory committees or review panels for Amgen; AstraZeneca; Daiichi Sankyo; Lilly; Novartis; Pfizer; Roche; and Seattle Genetics. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Vidal has disclosed that he has received honoraria for promotional speaker’s bureaus from Lilly, Pfizer, Puma, and Novartis. He disclosed as an independent contractor for Celcuity and Puma. He also disclosed membership on advisory committees or review panels for Lilly, Immunomedics, Novartis, and Puma. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wartman has disclosed that he has received consulting fees from Incyte. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Welch has disclosed that he has received consulting fees from Rigel Pharmaceuticals. He also disclosed honoraria for promotional speaker’s bureau and research support from Janssen Pharmaceuticals. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Angela Zimmermann, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Brooke Balun, MSN, APRN-BC, AOCNP (lead nurse planner) – no relevant financial relationships
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

Charles W. Willis, MBA, Director of Continuing Education from the Annenberg Center for Health Sciences at Eisenhower receives consulting fees from Pfizer; Amanda Sewell, MBA, Manager of Continuing Education, and Melissa Velasquez, Accreditation Specialist from the Annenberg Center for Health Sciences at Eisenhower, have no relevant commercial relationships to disclose.

The PIM planners and managers; Trace Hutchison, PharmD; Samantha Mattiucci, PharmD, CHCP; Judi Smelker-Mitchek, MBA, MSN, RN; and Amanda Glazar, PhD, CHCP; have nothing to disclose.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.